Title:
ANTIBODIES SPECIFICALLY BIND TO HER2
Document Type and Number:
Japanese Patent JP2018008954
Kind Code:
A
Abstract:
PROBLEM TO BE SOLVED: To provide antibodies against HER2 (human epidermal cell growth factor receptor 2) for prevention or treatment of cancer.SOLUTION: The invention provides an antibody that specifically binds to HER2 which is excessively expressed in cancer cells (in particular, breast cancer and gastric cancer cells), where the antibody specifically binds to an epitope on HER2 different from the epitope trastuzumab binds. The CDR sequence of the antibody has a low homology to the CDR sequences of known HER2 antibodies, which means the CDR sequence is unique. The combination of the antibody and trastuzumab has significantly enhanced cytotoxicity to kill cancer cells, so that very effective for treatment of cancer (in particular, breast cancer and gastric cancer). The remarkable efficacy of concomitant administration of the antibody of the present invention shows, without wishing to be bound by theory, that the antibody of the invention binds to an epitope of HER2 different from an epitope to which trastuzumab binds, thereby inhibiting HER2 cooperatively with trastuzumab.SELECTED DRAWING: None
More Like This:
Inventors:
LEE JONG-SEO
KIM KYU-TAE
LEE YOUNG-HA
LEE SOOK-YEON
HWANG IN-SIK
KO BONG-KOOK
KIM KYU-TAE
LEE YOUNG-HA
LEE SOOK-YEON
HWANG IN-SIK
KO BONG-KOOK
Application Number:
JP2017132833A
Publication Date:
January 18, 2018
Filing Date:
July 06, 2017
Export Citation:
Assignee:
ABCLON INC
International Classes:
C07K16/28; A61K39/395; A61P5/08; A61P5/26; A61P7/00; A61P9/10; A61P13/12; A61P17/02; A61P35/00; C12N15/09
Other References:
BMC CANCER, vol. Vol. 12:450, JPN6016025839, 2012, pages p. 1-16
HYBRIDOMA, vol. Vol. 30, No. 4, JPN6016025841, 2011, pages p. 347-353
CANCER RES., vol. Vol. 69, JPN6016025842, 2009, pages p. 9330-9336
HYBRIDOMA, vol. Vol. 30, No. 4, JPN6016025841, 2011, pages p. 347-353
CANCER RES., vol. Vol. 69, JPN6016025842, 2009, pages p. 9330-9336
Attorney, Agent or Firm:
Takuji Yamada
Michiko Matsutani
Sakurai Yoko
Michiko Matsutani
Sakurai Yoko
Previous Patent: Modulation of tumor immunity
Next Patent: A pharmacological constituent, its manufacturing method, and the directions for a SHK base
Next Patent: A pharmacological constituent, its manufacturing method, and the directions for a SHK base